Back to top
more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$35.48 USD

35.48
302,816

-0.46 (-1.28%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for COLL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 311 174 186 174 170
Receivables 180 183 106 83 73
Notes Receivable 0 0 0 0 0
Inventories 32 47 17 16 10
Other Current Assets 15 17 6 5 3
Total Current Assets 538 420 316 278 256
Net Property & Equipment 16 20 19 19 12
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 26 24 78 0 0
Intangibles 556 701 269 336 30
Deposits & Other Assets 2 3 3 3 0
Total Assets 1,143 1,174 692 644 306
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 9 3 4 10 6
Current Portion Long-Term Debt 183 163 48 48 4
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 265 267 226 181 191
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 458 434 280 239 202
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 262 141 140 100 0
Long-Term Debt 222 398 62 110 8
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 948 979 489 458 219
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 566 538 502 519 447
Retained Earnings -233 -281 -256 -333 -360
Other Equity 0 0 0 0 0
Treasury Stock 137 62 43 0 0
Total Shareholder's Equity 195 195 203 186 87
Total Liabilities & Shareholder's Equity 1,143 1,174 692 644 306
Total Common Equity 195 195 203 186 87
Shares Outstanding 32.60 33.50 34.50 34.50 33.50
Book Value Per Share 5.99 5.82 5.88 5.39 2.61

Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 311 305 325 269
Receivables NA 180 182 167 179
Notes Receivable NA 0 0 0 0
Inventories NA 32 34 26 33
Other Current Assets NA 15 17 18 17
Total Current Assets NA 538 537 537 498
Net Property & Equipment NA 16 17 18 19
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 26 26 25 24
Intangibles NA 556 590 626 664
Deposits & Other Assets NA 2 2 1 3
Total Assets NA 1,143 1,178 1,214 1,214
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 4 2 3
Current Portion Long-Term Debt NA 183 183 183 183
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 265 277 248 225
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 458 465 435 413
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 262 262 262 261
Long-Term Debt NA 222 266 310 354
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 948 999 1,013 1,035
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 566 546 548 540
Retained Earnings NA -233 -265 -286 -299
Other Equity NA 0 0 0 0
Treasury Stock NA 137 102 62 62
Total Shareholder's Equity NA 195 179 201 180
Total Liabilities & Shareholder's Equity NA 1,143 1,178 1,214 1,214
Total Common Equity 0 195 179 201 180
Shares Outstanding 31.90 32.60 34.70 34.60 34.50
Book Value Per Share 0.00 5.99 5.15 5.80 5.21